Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX
Amber E. Alsop
Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK
Search for more papers by this authorKaren Taylor
Cancer Research UK and University of Edinburgh, Cancer Research Centre, Edinburgh, Scotland
Search for more papers by this authorJieqing Zhang
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorHani Gabra
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorAdam J. W. Paige
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorCorresponding Author
Paul A. W. Edwards
Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK
Hutchison/MRC Research Centre, Addenbrookes Site, Hills Road, Cambridge, CB2 0XZ, UKSearch for more papers by this authorAmber E. Alsop
Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK
Search for more papers by this authorKaren Taylor
Cancer Research UK and University of Edinburgh, Cancer Research Centre, Edinburgh, Scotland
Search for more papers by this authorJieqing Zhang
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorHani Gabra
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorAdam J. W. Paige
Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Department of Oncology, Imperial College London, Hammersmith Hospital Campus, London, UK
Search for more papers by this authorCorresponding Author
Paul A. W. Edwards
Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK
Hutchison/MRC Research Centre, Addenbrookes Site, Hills Road, Cambridge, CB2 0XZ, UKSearch for more papers by this authorAbstract
Homozygous deletions in cancer cells have been thought to harbor tumor suppressor genes. We show that the 25 and 50 kb homozygous deletions in WWOX in the colon cancer cell line HCT116 result from a complex set of heterozygous deletions, some of which overlap to give homozygous loss. One of the heterozygous deletions has removed exons 6–8 of one allele of WWOX, and there is also a third copy of the distal region of WWOX in an unbalanced translocation. The exon 6–8 deletion results in allele-specific expression of a deleted transcript, which seems likely to be the main biological consequence of the deletions, since similar transcripts are found in other tumors. We show that such a complex set of deletions could form in a single exchange event between two homologous chromosomes, so that the selective advantage of such rearrangements need not be within the homozygous deletion. We conclude that homozygous deletions can be markers of complex rearrangements that have targets outside the homozygous deletion itself and that the target of deletions in the FRA16D region is indeed WWOX, the common outcome being the removal of particular WWOX exons. This article contains supplementary material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat. © 2008 Wiley-Liss, Inc.
Supporting Information
Filename | Description |
---|---|
gcc20548-SupplementaryFigure1.tiff3.7 MB | Supplementary Figure 1 - Array-CGH data for the region approximately 76.3 to 78 Mb on chromosome 16, on a custom oligonucleotide array from Nimblegen Systems.Points were data averaged over 300 bp windows. Line is estimated copy number obtained using the circular binary segmentation algorithm of Olshen et al (2004). |
gcc20548-SupplementaryTable1.gff771.5 KB | Supplementary Table 1 - Array-CGH data in GFF format (specified at http://www.sanger.ac.uk/Software/formats/GFF/) for the region approximately 76.3 to 78 Mb on chromosome 16, on a custom oligonucleotide array from Nimblegen Systems.This file contains the array-CGH data averaged over 300 bp intervals. It is a tab-delimited text file and can be opened in Microsoft Excel or any text editor. The columns are respectively <chromosome> <software used to process data data> <samplename> <start position on chromosome 16, hg17 assembly> <end position on chromosome 16, hg17 assembly> <hybridisation signal ratio> <not used> <not used> <color for plotting>Most of the rows have color 000000. These are the array CGH data. The last few rows, for which color is FF0000, are lines representing regions of constant copy number as calculated by the Olshen segmentation algorithm (see methods). |
gcc20548-SupplementaryTable1.xls3.5 MB | Supplementary Table 1 - Array-CGH data in GFF format (specified at http://www.sanger.ac.uk/Software/formats/GFF/) for the region approximately 76.3 to 78 Mb on chromosome 16, on a custom oligonucleotide array from Nimblegen Systems.This file contains the array-CGH data averaged over 300 bp intervals. It is a tab-delimited text file and can be opened in Microsoft Excel or any text editor. The columns are respectively <chromosome> <software used to process data data> <samplename> <start position on chromosome 16, hg17 assembly> <end position on chromosome 16, hg17 assembly> <hybridisation signal ratio> <not used> <not used> <color for plotting>Most of the rows have color 000000. These are the array CGH data. The last few rows, for which color is FF0000, are lines representing regions of constant copy number as calculated by the Olshen segmentation algorithm (see methods). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Abdel-Rahman WM,Katsura K,Rens W,Gorman PA,Sheer D,Bicknell D,Bodmer WF,Arends MJ,Wyllie AH,Edwards PA. 2001. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci USA 98: 2538–2543.
- Alsop AE,Miethke P,Rofe R,Koina E,Sankovic N,Deakin JE,Haines H,Rapkins RW,Marshall Graves JA. 2005. Characterizing the chromosomes of the Australian model marsupial Macropus eugenii (tammar wallaby). Chromosome Res 13: 627–636.
- Alsop AE,Teschendorff AE,Edwards PA. 2006. Distribution of breakpoints on chromosome 18 in breast, colorectal, and pancreatic carcinoma cell lines. Cancer Genet Cytogenet 164: 97–109.
- Aqeilan RI,Palamarchuk A,Weigel RJ,Herrero JJ,Pekarsky Y,Croce CM. 2004a. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2γ transcription factor. Cancer Res 64: 8256–8261.
- Aqeilan RI,Pekarsky Y,Herrero JJ,Palamarchuk A,Letofsky J,Druck T,Trapasso F,Han SY,Melino G,Huebner K,Croce CM. 2004b. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 101: 4401–4406.
- Aqeilan RI,Donati V,Palamarchuk A,Trapasso F,Kaou M,Pekarsky Y,Sudol M,Croce CM. 2005. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764– 6772.
- Aqeilan RI,Trapasso F,Hussain S,Costinean S,Marshall D,Pekarsky Y,Hagan JP,Zanesi N,Kaou M,Stein GS,Lian JB,Croce CM. 2007. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949–3954.
- Bednarek AK,Laflin KJ,Daniel RL,Liao Q,Hawkins KA,Aldaz CM. 2000. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140–2145.
- Bednarek AK,Keck-Waggoner CL,Daniel RL,Laflin KJ,Bergsagel PL,Kiguchi K,Brenner AJ,Aldaz CM. 2001. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61: 8068–8073.
- Boldog F,Gemmill RM,West J,Robinson M,Robinson L,Li E,Roche J,Todd S,Waggoner B,Lundstrom R,Jacobson J,Mullokandov MR,Klinger H,Drabkin HA. 1997. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 6: 193–203.
- Chang NS,Pratt N,Heath J,Schultz L,Sleve D,Carey GB,Zevotek N. 2001. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276: 3361–3370.
- Chesi M,Bergsagel PL,Shonukan OO,Martelli ML,Brents LA,Chen T,Schrock E,Ried T,Kuehl WM. 1998. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91: 4457–4463.
- Cox C,Bignell G,Greenman C,Stabenau A,Warren W,Stephens P,Davies H,Watt S,Teague J,Edkins S,Birney E,Easton DF,Wooster R,Futreal PA,Stratton MR. 2005. A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci USA 102: 4542–4547.
- Driouch K,Prydz H,Monese R,Johansen H,Lidereau R,Frengen E. 2002. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21: 1832–1840.
- Fabbri M,Iliopoulos D,Trapasso F,Aqeilan RI,Cimmino A,Zanesi N,Yendamuri S,Han SY,Amadori D,Huebner K,Croce CM. 2005. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102: 15611–15616.
- Finnis M,Dayan S,Hobson L,Chenevix-Trench G,Friend K,Ried K,Venter D,Woollatt E,Baker E,Richards RI. 2005. Common chromosomal fragile site FRA16D mutation in cancer cells. Hum Mol Genet 14: 1341–1349.
- Gourley C,Paige AJ,Taylor KJ,Scott D,Francis NJ,Rush R,Aldaz CM,Smyth JF,Gabra H. 2005. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 26: 1681–1689.
- Gribble SM,Prigmore E,Burford DC,Porter KM,Ng BL,Douglas EJ,Fiegler H,Carr P,Kalaitzopoulos D,Clegg S,Sandstrom R,Temple IK,Youings SA,Thomas NS,Dennis NR,Jacobs PA,Crolla JA,Carter NP. 2005. The complex nature of constitutional de novo apparently balanced translocations in patients presenting with abnormal phenotypes. J Med Genet 42: 8–16.
- Hahn SA,Schutte M,Hoque AT,Moskaluk CA,da Costa LT,Rozenblum E,Weinstein CL,Fischer A,Yeo CJ,Hruban RH,Kern SE. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350–353.
- Inoue H,Ishii H,Alder H,Snyder E,Druck T,Huebner K,Croce CM. 1997. Sequence of the FRA3B common fragile region: Implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 94: 14584–14589.
- Kamb A,Gruis NA,Weaver-Feldhaus J,Liu Q,Harshman K,Tavtigian SV,Stockert E,Day RS,III,Johnson BE,Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.
- Kuroki T,Yendamuri S,Trapasso F,Matsuyama A,Aqeilan RI,Alder H,Rattan S,Cesari R,Nolli ML,Williams NN,Mori M,Kanematsu T,Croce CM. 2004. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10: 2459–2465.
- Mangelsdorf M,Ried K,Woollatt E,Dayan S,Eyre H,Finnis M,Hobson L,Nancarrow J,Venter D,Baker E,Richards RI. 2000. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 60: 1683–1689.
- Nunez MI,Ludes-Meyers J,Abba MC,Kil H,Abbey NW,Page RE,Sahin A,Klein-Szanto AJ,Aldaz CM. 2005a. Frequent loss of WWOX expression in breast cancer: Correlation with estrogen receptor status. Breast Cancer Res Treat 89: 99–105.
- Nunez MI,Rosen DG,Ludes-Meyers JH,Abba MC,Kil H,Page R,Klein-Szanto AJ,Godwin AK,Liu J,Mills GB,Aldaz CM. 2005b. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5: 64.
- O'Keefe LV,Richards RI. 2006. Common chromosomal fragile sites and cancer: Focus on FRA16D. Cancer Lett 232: 37–47.
- Olshen AB,Venkatraman ES,Lucito R,Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557–572.
- Paige AJ,Taylor KJ,Stewart A,Sgouros JG,Gabra H,Sellar GC,Smyth JF,Porteous DJ,Watson JE. 2000. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60: 1690–1697.
- Paige AJ,Taylor KJ,Taylor C,Hillier SG,Farrington S,Scott D,Porteous DJ,Smyth JF,Gabra H,Watson JE. 2001. WWOX: A candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98: 11417–11422.
- Pimenta FJ,Gomes DA,Perdigao PF,Barbosa AA,Romano-Silva MA,Gomez MV,Aldaz CM,De Marco L,Gomez RS. 2006. Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer 118: 1154–1158.
- Pole JC,Courtay-Cahen C,Garcia MJ,Blood KA,Cooke SL,Alsop AE,Tse DM,Caldas C,Edwards PA. 2006. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 25: 5693–5706.
- Putnam CD,Pennaneach V,Kolodner RD. 2005. Saccharomyces cerevisiae as a model system to define the chromosomal instability phenotype. Mol Cell Biol 25: 7226–7238.
- Ried K,Finnis M,Hobson L,Mangelsdorf M,Dayan S,Nancarrow JK,Woollatt E,Kremmidiotis G,Gardner A,Venter D,Baker E,Richards RI. 2000. Common chromosomal fragile site FRA16D sequence: Identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9: 1651–1663.
- Rousseau-Merck MF,Versteege I,Legrand I,Couturier J,Mairal A,Delattre O,Aurias A. 1999. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59: 3152–3156.
- Schutte M,da Costa LT,Hahn SA,Moskaluk C,Hoque AT,Rozenblum E,Weinstein CL,Bittner M,Meltzer PS,Trent JM,Yeo CJ,Hruban RH,Kern SE. 1995. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 92: 5950–5954.
- Sinclair PB,Nacheva EP,Leversha M,Telford N,Chang J,Reid A,Bench A,Champion K,Huntly B,Green AR. 2000. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95: 738–743.